Michele W.L. Teng

University of Queensland — Australia

Medicine · Health Sciences

69h-index22.4kcitations344works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(148), CAR-T cell therapy research(135), Immunotherapy and Immune Responses(109), Immune Cell Function and Interaction(108), Monoclonal and Polyclonal Antibodies Research(48)

Publications344 total

TIGIT predominantly regulates the immune response via regulatory T cells
Journal of Clinical Investigation·2024· 4 citedOpen Access
Author Correction: Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cell
Nature Immunology·2024· 2 citedOpen Access
Author Correction: The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
Nature Immunology·2024· 1 citedOpen Access
Supplementary Methods and Legends from CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function
2023Open Access
Supplementary Figures from Control of Metastases via Myeloid CD39 and NK Cell Effector Function
2023Open Access
Supplementary Data from CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function
2023Open Access
Supplementary Methods and Legends from CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function
2023Open Access
Data from CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function
2023Open Access
Data from Control of Metastases via Myeloid CD39 and NK Cell Effector Function
2023Open Access
Supplementary Data from CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function
2023Open Access
Data from CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function
2023Open Access
Supplementary Figures from Control of Metastases via Myeloid CD39 and NK Cell Effector Function
2023Open Access
Data from Control of Metastases via Myeloid CD39 and NK Cell Effector Function
2023Open Access
Supplementary Methods, Figure Legends, Table S1 from Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
2023Open Access
Supplementary Figure S5 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
2023Open Access
Supplementary Figure S4 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
2023Open Access
Supp. Fig. 1 from Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23
2023Open Access
Supp. Fig. 1 from Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23
2023Open Access
Supplementary Figure S1 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
2023Open Access
Supplementary Figure S3 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
2023Open Access
page 1 of 18Next →

Frequent Co-authors

Mark J. Smyth(47), Shin Foong Ngiow(15), Phillip K. Darcy(7), Jake S. O’Donnell(6), Arabella Young(6), Michael H. Kershaw(6), Stephen J. Blake(5), Kyohei Nakamura(5), Geoffrey R. Hill(5), Antoni Ribas(4), Michelle C.R. Yong(4), Kazuyoshi Takeda(4), Tobias Bald(4), Juming Yan(4), Laurence Zitvogel(4), Bianca von Scheidt(4), Joseph A. Trapani(4), Jing Liu(3), Stacey Allen(3), Michael Hölzel(3)